Shandong Boan Biotechnology CDE IND application accepted for BA2201
Shandong Boan Biotechnology said its CDE IND application has been accepted for the TLLA/IL-23 bispecific antibody BA2201.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Shandong Boan Biotechnology said its CDE IND application has been accepted for the TLLA/IL-23 bispecific antibody BA2201.